Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation In Vivo

Yunfeng Sun; Honghua Pan; Shenghui Shen; Zhongni Xia; Zhongmin Yu; ChengLe Li; Pingping Sun; Chuanwei Xin

doi:10.12659/MSM.921738

16 July 2020: Animal Study

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation

Yunfeng Sun ^12AEG , Honghua Pan ^12CD , Shenghui Shen ^23ABCF , Zhongni Xia ^12BC , Zhongmin Yu ^2ABCD , ChengLe Li ^12F , Pingping Sun ^12DEG* , Chuanwei Xin ^12DG*

DOI: 10.12659/MSM.921738

Med Sci Monit 2020; 26:e921738

Authors information Article notes Copyright and License information

View HTML version

Figure 5 Pictorial abstract showing how Alisma Shugan Decoction (ASD) ameliorated hepatotoxicity and associated liver dysfunction. The present study provides new insights into the hepato-protective effects of ASD.

Back to the Article

Alisma Shugan Decoction (ASD) Ameliorates Hepatotoxicity and Associated Liver Dysfunction by Inhibiting Oxidative Stress and p65/Nrf2/JunD Signaling Dysregulation

Your Privacy